Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study

被引：2

作者：

Arai, Junya ^{[1
,2
]}

Niikura, Ryota ^{[1
,3
]}

Hayakawa, Yoku ^{[1
]}

Suzuki, Nobumi ^{[1
]}

Honda, Tetsuro ^{[4
]}

Okamura, Takuma ^{[4
]}

Hasatani, Kenkei ^{[5
]}

Yoshida, Naohiro ^{[6
]}

Nishida, Tsutomu ^{[7
]}

Sumiyoshi, Tetsuya ^{[8
]}

Kiyotoki, Shu ^{[9
]}

Ikeya, Takashi ^{[10
]}

Arai, Masahiro ^{[11
]}

Boku, Narikazu ^{[1
]}

Fujishiro, Mitsuhiro ^{[1
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan

[2] Asahi Life Fdn, Inst Med Sci, Dept Gastroenterol, Tokyo, Japan

[3] Tokyo Med Univ, Gastroenterol Endoscopy, Tokyo, Japan

[4] Nagasaki Harbor Med Ctr, Dept Gastroenterol, Nagasaki, Japan

[5] Fukui Prefectural Hosp, Dept Gastroenterol, Fukui, Japan

[6] Ishikawa Prefectural Cent Hosp, Dept Gastroenterol, Kanazawa, Ishikawa, Japan

[7] Toyonaka City Hosp, Dept Gastroenterol, Osaka, Japan

[8] Tonan Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[9] Shuto Gen Hosp, Dept Gastroenterol, Yamaguchi, Japan

[10] St Lukes Int Hosp, Dept Gastroenterol, Tokyo, Japan

[11] Nerima Hikarigaoka Hosp, Dept Gastroenterol, Tokyo, Japan

来源：

CANCER MEDICINE | 2023年

关键词：

CBM588; gastric cancer; nivolumab; probiotics;

D O I：

10.1002/cam4.6313

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundPrevious studies have revealed an association between probiotic use and effectiveness of immune checkpoint inhibitors in renal and lung cancers. However, little is known regarding other cancers, including gastrointestinal cancer. MethodsTo address this issue, we conducted a multicenter retrospective cohort study and the duration of nivolumab treatment for various cancers was compared between probiotic users and non-users. Results and ConclusionsIn total, 488 patients who received nivolumab therapy were included. In all cancers, no significant differences in treatment duration of nivolumab were observed between probiotic users and non-users (median 62.0 vs. 56.0, hazard ratio = 1.02, p = 0.825), whereas probiotic use, compared with non-use, in patients with gastric cancer was significantly associated with a longer duration of nivolumab treatment (55.0 vs. 31.0 days, hazard ratio = 0.69, p = 0.039). In conclusion, probiotics may improve the response to nivolumab and potentially prolong progression-free survival in patients with gastric cancer.

引用

页码：16876 / 16880

页数：5

共 18 条

[1] Use of Antibiotics and Probiotics Reduces the Risk of Metachronous Gastric Cancer after Endoscopic Resection [J].

Arai, Junya ;

Niikura, Ryota ;

Hayakawa, Yoku ;

Kawahara, Takuya ;

Honda, Tetsuro ;

Hasatani, Kenkei ;

Yoshida, Naohiro ;

Nishida, Tsutomu ;

Sumiyoshi, Tetsuya ;

Kiyotoki, Shu ;

Ikeya, Takashi ;

Arai, Masahiro ;

Suzuki, Nobumi ;

Tsuji, Yosuke ;

Yamada, Atsuo ;

Kawai, Takashi ;

Koike, Kazuhiko .

BIOLOGY-BASEL, 2021, 10 (06)

[2] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].

CHARLSON, ME ;

POMPEI, P ;

ALES, KL ;

MACKENZIE, CR .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383

[3] Spatial distribution of live gut microbiota and bile acid metabolism in various parts of human large intestine [J].

Chinda, Daisuke ;

Takada, Toshihiko ;

Mikami, Tatsuya ;

Shimizu, Kensuke ;

Oana, Kosuke ;

Arai, Tetsu ;

Akitaya, Kazuki ;

Sakuraba, Hirotake ;

Katto, Miyuki ;

Nagara, Yusuke ;

Makino, Hiroshi ;

Fujii, Daichi ;

Oishi, Kenji ;

Fukuda, Shinsaku .

SCIENTIFIC REPORTS, 2022, 12 (01)

[4] Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial [J].

Dizman, Nazli ;

Meza, Luis ;

Bergerot, Paulo ;

Alcantara, Marice ;

Dorff, Tanya ;

Lyou, Yung ;

Frankel, Paul ;

Cui, Yujie ;

Mira, Valerie ;

Llamas, Marian ;

Hsu, Joann ;

Zengin, Zeynep ;

Salgia, Nicholas ;

Salgia, Sabrina ;

Malhotra, Jasnoor ;

Chawla, Neal ;

Chehrazi-Raffle, Alex ;

Muddasani, Ramya ;

Gillece, John ;

Reining, Lauren ;

Trent, Jeff ;

Takahashi, Motomichi ;

Oka, Kentaro ;

Higashi, Seiya ;

Kortylewski, Marcin ;

Highlander, Sarah K. ;

Pal, Sumanta K. .

NATURE MEDICINE, 2022, 28 (04) :704-+

[5] Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients [J].

Gopalakrishnan, V. ;

Spencer, C. N. ;

Nezi, L. ;

Reuben, A. ;

Andrews, M. C. ;

Karpinets, T. V. ;

Prieto, P. A. ;

Vicente, D. ;

Hoffman, K. ;

Wei, S. C. ;

Cogdill, A. P. ;

Zhao, L. ;

Hudgens, C. W. ;

Hutchinson, D. S. ;

Manzo, T. ;

de Macedo, M. Petaccia ;

Cotechini, T. ;

Kumar, T. ;

Chen, W. S. ;

Reddy, S. M. ;

Sloane, R. Szczepaniak ;

Galloway-Pena, J. ;

Jiang, H. ;

Chen, P. L. ;

Shpall, E. J. ;

Rezvani, K. ;

Alousi, A. M. ;

Chemaly, R. F. ;

Shelburne, S. ;

Vence, L. M. ;

Okhuysen, P. C. ;

Jensen, V. B. ;

Swennes, A. G. ;

McAllister, F. ;

Sanchez, E. Marcelo Riquelme ;

Zhang, Y. ;

Le Chatelier, E. ;

Zitvogel, L. ;

Pons, N. ;

Austin-Breneman, J. L. ;

Haydu, L. E. ;

Burton, E. M. ;

Gardner, J. M. ;

Sirmans, E. ;

Hu, J. ;

Lazar, A. J. ;

Tsujikawa, T. ;

Diab, A. ;

Tawbi, H. ;

Glitza, I. C. .

SCIENCE, 2018, 359 (6371) :97-103

[6] Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial [J].

Kang, Yoon-Koo ;

Chen, Li-Tzong ;

Ryu, Min-Hee ;

Oh, Do-Youn ;

Oh, Sang Cheul ;

Chung, Hyun Cheol ;

Lee, Keun-Wook ;

Omori, Takeshi ;

Shitara, Kohei ;

Sakuramoto, Shinichi ;

Chung, Ik-Joo ;

Yamaguchi, Kensei ;

Kato, Ken ;

Sym, Sun Jin ;

Kadowaki, Shigenori ;

Tsuji, Kunihiro ;

Chen, Jen-Shi ;

Bai, Li-Yuan ;

Oh, Sung-Yong ;

Choda, Yasuhiro ;

Yasui, Hisateru ;

Takeuchi, Kentaro ;

Hirashima, Yoshinori ;

Hagihara, Shunsuke ;

Boku, Narikazu .

LANCET ONCOLOGY, 2022, 23 (02) :234-247

[7] Chemotherapy Maintenance [J].

Kasi, Pashtoon Murtaza ;

Grothey, Axel .

CANCER JOURNAL, 2016, 22 (03) :199-204

[8] Microbiota in the stomach and application of probiotics to gastroduodenal diseases [J].

Koga, Yasuhiro .

WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (47) :6702-6715

[9] Non-Helicobacter pylori Gastric Microbiome Modulates Prooncogenic Responses and Is Associated With Gastric Cancer Risk [J].

Niikura, Ryota ;

Hayakawa, Yoku ;

Nagata, Naoyoshi ;

Miyoshi-Akiayama, Tohru ;

Miyabayashi, Koji ;

Tsuboi, Mayo ;

Suzuki, Nobumi ;

Hata, Masahiro ;

Arai, Junya ;

Kurokawa, Ken ;

Abe, Sohei ;

Uekura, Chie ;

Miyoshi, Kotaro ;

Ihara, Sozaburo ;

Hirata, Yoshihiro ;

Yamada, Atsuo ;

Fujiwara, Hiroaki ;

Ushiku, Tetsuo ;

Woods, Susan L. ;

Worthley, Daniel L. ;

Hatakeyama, Masanori ;

Han, Yiping W. ;

Wang, Timothy C. ;

Kawai, Takashi ;

Fujishiro, Mitsuhiro .

GASTRO HEP ADVANCES, 2023, 2 (05) :684-700

[10] Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors [J].

Nomura, Motoo ;

Nagatomo, Ryosuke ;

Doi, Keitaro ;

Shimizu, Juko ;

Baba, Kiichiro ;

Saito, Tomoki ;

Matsumoto, Shigemi ;

Inoue, Koichi ;

Muto, Manabu .

JAMA NETWORK OPEN, 2020, 3 (04) :e202895

← 1 2 →